Artificial Blood Vessels Market By Application (Aortic Disease, Peripheral Artery Disease, Hemodialysis), By Polymer Type (Polydioxanone, Elastomer, Polyethylene Terephthalate), By End-User Industry (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Artificial Blood Vessels Market was valued at USD 2.2 Billion in 2024-e and will surpass USD 3.1 Billion by 2030; growing at a CAGR of 6.0% during 2025-2030.

The artificial blood vessels market is experiencing significant growth, driven by the rising incidence of cardiovascular diseases, increasing demand for vascular grafts, and advancements in biomaterials. The need for artificial blood vessels is particularly growing in patients requiring vascular reconstruction due to trauma, chronic illnesses, or congenital conditions. Technological advancements and research into bioengineered and synthetic grafts are further propelling the market. The market is segmented based on application, polymer type, and end-user, with different segments exhibiting varying growth dynamics.

Aortic Disease Segment is the Largest Owing to High Demand for Grafts

Aortic diseases, including aneurysms and dissections, require immediate and effective treatment, making this segment the largest in the artificial blood vessels market. The increasing prevalence of aortic aneurysms, particularly among the aging population, is a major factor driving demand. Open surgical repair and endovascular aneurysm repair (EVAR) procedures are increasingly utilizing artificial grafts to replace damaged blood vessels, ensuring durability and improved patient outcomes.

Additionally, advancements in synthetic vascular grafts, particularly those made from polyethylene terephthalate (PET) and polytetrafluoroethylene (PTFE), have significantly improved surgical outcomes in aortic disease treatment. Market players are focusing on the development of long-lasting, biocompatible solutions that reduce the risk of infections and thrombosis, further solidifying the dominance of this segment.

Peripheral Artery Disease Segment is the Fastest Growing Owing to Increasing Prevalence

Peripheral artery disease (PAD) is witnessing rapid growth due to the increasing prevalence of diabetes and hypertension, which are key risk factors for vascular blockages. The demand for artificial blood vessels in this segment is driven by the growing number of minimally invasive procedures, including peripheral bypass surgeries, which require durable and flexible graft materials.

Developments in bioresorbable vascular grafts and tissue-engineered blood vessels have enabled better clinical outcomes in PAD patients. Companies are also investing in research to develop grafts with enhanced patency rates, reducing the need for repeated interventions. The increasing preference for minimally invasive surgical techniques is expected to sustain the high growth rate of this segment.

Hemodialysis Segment is Growing Due to Rising Chronic Kidney Disease Cases

The rising global burden of chronic kidney disease (CKD) is driving the demand for artificial blood vessels in hemodialysis. Patients with end-stage renal disease (ESRD) require vascular access for dialysis, and synthetic grafts serve as an essential alternative when native vein access is not viable. The increasing number of patients undergoing long-term dialysis is fueling the growth of this segment.

The introduction of advanced polymer-based grafts with improved biocompatibility and resistance to infections has enhanced treatment efficiency for hemodialysis patients. Moreover, artificial blood vessels designed for dialysis access are undergoing continuous improvements to prevent complications like stenosis and thrombosis, further supporting market growth.

Polydioxanone Segment is the Fastest Growing Owing to Biodegradable Properties

Polydioxanone-based artificial blood vessels are experiencing rapid adoption due to their biodegradable and bioresorbable properties. Unlike traditional synthetic grafts, polydioxanone grafts gradually dissolve in the body, eliminating long-term complications associated with permanent implants. This makes them particularly beneficial for pediatric patients and temporary vascular reconstruction procedures.

As research into bioengineered blood vessels advances, polydioxanone grafts are becoming a preferred choice for applications where long-term synthetic grafts may not be ideal. Regulatory approvals and ongoing clinical trials for novel bioresorbable vascular grafts are expected to accelerate the growth of this segment in the coming years.

Polyethylene Terephthalate Segment is the Largest Owing to Durability and Widespread Use

Polyethylene terephthalate (PET)-based artificial blood vessels are the most widely used due to their durability, flexibility, and long-term patency rates. PET grafts have been extensively used in aortic and peripheral vascular surgeries for decades, making this segment the largest in the polymer type category.

Continuous improvements in PET-based vascular grafts, such as the development of heparin-coated grafts to improve blood compatibility, are further strengthening market demand. Additionally, the ability of PET grafts to resist biodegradation makes them suitable for long-term vascular reconstructions, ensuring their dominance in the artificial blood vessels market.

Hospitals Segment is the Largest Owing to High Surgical Volume

Hospitals remain the largest end-user segment due to the high volume of vascular surgeries performed in these settings. Advanced medical infrastructure, availability of skilled surgeons, and the presence of specialized cardiovascular departments contribute to the dominance of this segment.

Leading hospitals worldwide are increasingly adopting next-generation artificial blood vessels with improved biocompatibility and reduced rejection rates. Collaborations between hospitals and research institutes are further driving innovation in vascular graft technology, ensuring continued growth in this segment.

Ambulatory Surgical Centers Segment is the Fastest Growing Owing to Minimally Invasive Procedures

Ambulatory surgical centers (ASCs) are emerging as the fastest-growing segment due to the increasing preference for outpatient vascular procedures. The shift towards minimally invasive surgeries, which require shorter hospital stays and reduce overall healthcare costs, is driving the adoption of artificial blood vessels in ASCs.

The availability of advanced vascular grafts compatible with endovascular procedures is further enhancing the growth of this segment. As more ASCs adopt cutting-edge technologies, the demand for flexible and biocompatible artificial blood vessels is expected to rise significantly.

North America is the Largest Market Owing to High Healthcare Expenditure

North America holds the largest share in the artificial blood vessels market due to its well-established healthcare infrastructure, high healthcare spending, and significant investments in vascular research. The region is home to leading medical device manufacturers and research institutes actively engaged in developing innovative vascular grafts.

The prevalence of cardiovascular diseases and chronic kidney diseases in the U.S. and Canada has further fueled demand for artificial blood vessels. Favorable reimbursement policies and regulatory approvals for advanced vascular graft technologies are expected to sustain North America's dominance in this market.

Competitive Landscape and Leading Companies

The artificial blood vessels market is highly competitive, with major players focusing on research, innovation, and strategic collaborations to enhance their product offerings. Key companies such as B. Braun Melsungen AG, Medtronic plc, Terumo Medical Corporation, and Humacyte Inc. are at the forefront of developing next-generation vascular grafts.

Mergers and acquisitions, regulatory approvals, and new product launches are shaping the competitive landscape. Companies are investing in bioengineered blood vessels, biodegradable grafts, and polymer-based innovations to strengthen their market position. As demand for artificial blood vessels continues to rise, competition is expected to intensify, driving further advancements in vascular graft technology.

List of Leading Companies:

• B. Braun Melsungen AG
• Terumo Medical Corporation
• Medtronic plc
• Cook Medical Incorporated
• Becton, Dickinson and Company
• Humacyte Inc.
• JOTEC GmbH
• LeMaitre Vascular Inc.
• Techshot Inc.
• W. L. Gore & Associates, Inc.
• Boston Scientific Corporation
• Cardinal Health, Inc.
• Abbott Laboratories
• C. R. Bard, Inc.
• Stryker Corporation

Recent Developments:

• Humacyte has secured FDA approval for its bioengineered blood vessels designed to treat vascular trauma, marking a significant advancement in tissue engineering.
• Magenta Medical secured $105 million to advance its heart-pump technology, positioning itself as a competitor in the cardiovascular device market.
• Becton Dickinson has developed a new finger-prick blood testing device, offering a less invasive method for medical diagnostics.
• Humacyte's lab-grown arteries have demonstrated improved blood flow and reduced need for amputations in trauma patients during clinical trials.

Report Scope: